Holen Sie sich die Stockscreener-App
2.4599
0.20%
-0.0101
Schlusskurs vom Vortag:
$2.47
Offen:
$2.49
24-Stunden-Volumen:
3.52M
Relative Volume:
0.41
Marktkapitalisierung:
$2.33B
Einnahmen:
$1.31M
Nettoeinkommen (Verlust:
$-597.65M
KGV:
-2.536
EPS:
-0.97
Netto-Cashflow:
$-425.62M
1W Leistung:
+2.28%
1M Leistung:
-12.28%
6M Leistung:
-23.92%
1J Leistung:
-44.23%
1-Tages-Spanne:
$2.45
$2.54
1-Wochen-Bereich:
$2.33
$2.6353
52-Wochen-Spanne:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Firmenname
Immunitybio Inc
Sektor
Branche
Telefon
(844) 696-5235
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Vergleichen Sie IBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.465 | 2.31B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.10 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.89 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.39 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
641.42 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.35 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | BTIG Research | Buy |
| 2023-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Eingeleitet | Jefferies | Buy |
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Business Wire
ImmunityBio’s Shareholder Settlement Gains Preliminary Approval - The Globe and Mail
ImmunityBio Shareholder Settlement Gains Preliminary Approval, Boosting Company's Future Prospects - AInvest
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Why Investors Shouldn't Be Surprised By ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Q2 2025 Revenue Up 5% YoY to $1,241mln; Raises FY23 Guidance, Innovation Target. - AInvest
ImmunityBio Q2 Earnings Show 60% Revenue Growth, $153.7 Million in Cash, and Strong Sales Momentum. - AInvest
ImmunityBio's ANKTIVA Receives Buy Rating Amid Expanding Oncology Potential and Market Growth - AInvest
ImmunityBio Reports Q2 Earnings with 60% Revenue Increase, $43M in Sales, and 246% Unit Growth - AInvest
ImmunityBio 2025 Q2 Earnings Sustained Losses Amid Strong Revenue Surge - AInvest
ImmunityBio Reports Revenue Growth Amidst Continued Investments - TipRanks
ImmunityBio: Q2 Earnings Snapshot - Norwalk Hour
ImmunityBio's Q2 Net Loss Narrows, Revenue Rises - MarketScreener
ImmunityBio’s Revenue Jumps On Bladder Cancer Drug Success - Finimize
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
ImmunityBio: Boral Capital raises PT to $30, maintains Buy rating. - AInvest
ImmunityBio Q2 Financial Results: $92.6 Million LossNews and Statistics - IndexBox
Immunitybio Inc earnings beat, revenue topped estimates By Investing.com - Investing.com India
ImmunityBio, Inc. SEC 10-Q Report - TradingView
Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.10 a Share, vs. FactSet Est of $0.11 Loss - MarketScreener
Immunitybio Inc earnings beat, revenue topped estimates - Investing.com
ImmunityBio Q2 revenue up 60%, surpassing market estimates, on strong sales of ANKTIVA - MarketScreener
Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $26.4M, vs. FactSet Est of $23.1M - MarketScreener
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code - Yahoo Finance
ImmunityBio (IBRX) Announces Preliminary Financial Results for the Quarter Ended June 30 - MSN
Watch for Trend Continuation in ImmunityBio Inc. Next WeekCapital Growth With Controlled Risk Picks Suggested - beatles.ru
ImmunityBio Inc. Moves Into Overbought Range Analysts CautiousReal-Time Market Sentiment Tracking Gains Momentum - metal.it
What are the technical indicators suggesting about ImmunityBio Inc.Consistent high-performance stocks - Jammu Links News
What is the dividend policy of ImmunityBio Inc. stockInvest smarter with daily stock recommendations - Jammu Links News
Is ImmunityBio Inc. a growth stock or a value stockFree Stock Market Real-Time Monitoring - Jammu Links News
How strong is ImmunityBio Inc. company’s balance sheetGet exclusive market insights for better trading - Jammu Links News
10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey
Should I hold or sell ImmunityBio Inc. stock in 2025Explosive trading growth - Jammu Links News
Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations - MSN
What are analysts’ price targets for ImmunityBio Inc. in the next 12 monthsBuild a portfolio that stands the test of time - Jammu Links News
What are ImmunityBio Inc. company’s key revenue driversFree Stock Index Interpretation - Jammu Links News
What is ImmunityBio Inc. company’s growth strategyMassive portfolio appreciation - Jammu Links News
How many analysts rate ImmunityBio Inc. as a “Buy”Breakneck growth rates - Jammu Links News
What institutional investors are buying ImmunityBio Inc. stockInvest confidently with market-leading analysis - Jammu Links News
ImmunityBio’s Innovative Approach to Glioblastoma: A Promising Clinical Update - TipRanks
ImmunityBio’s Innovative Immunotherapy Trial: A Potential Game-Changer in Cancer Treatment - TipRanks
Finanzdaten der Immunitybio Inc-Aktie (IBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunitybio Inc-Aktie (IBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
| Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
| Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
| Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
| Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
| LAUER REGAN J | Chief Accounting Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
21,031 |
0 |
115,365 |
0.40%
2.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):